SCHEMBL24253505

SCHEMBL24253505

CC(C)Cc1nn(C)c2c1CN(C)CC2

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NMT1 P30419 2/20 0.38
CYP2C19 P33261 1/20 0.33
PDE2A O00408 1/20 0.33
MAOA P21397 4/20 0.33
MAOB P27338 4/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2D6 P10635 1/20 0.33
HTR1A P08908 1/20 0.32
ADRA2A P08913 1/20 0.32
ADRA2B P18089 1/20 0.32
ADRA2C P18825 1/20 0.32
SLC6A2 P23975 1/20 0.32
HTR1D P28221 1/20 0.32
HTR1B P28222 1/20 0.32
HTR2A P28223 1/20 0.32
HTR7 P34969 1/20 0.32
HRH1 P35367 1/20 0.32
DRD3 P35462 1/20 0.32
HTR2B P41595 1/20 0.32
HTR6 P50406 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22993457 0.87 NMT1 (0.38) NMT1CYP2C19PDE2A
SCHEMBL17234811 0.81 PDE10A (0.38) CYP2C19MAOAMAOBCYP1A2CYP2D6
SCHEMBL17229726 0.75 CYP2C19 (0.40) CYP2C19CYP1A2CYP2D6HTR1AADRA2A
SCHEMBL14971166 0.72 CYP2C19 (0.39) CYP2C19MAOAMAOBCYP1A2CYP2D6
SCHEMBL24253310 0.71 CYP2C19 (0.38) NMT1CYP2C19CYP1A2
SCHEMBL26373583 0.70 CYP2C19 (0.43) CYP2C19MAOAMAOBCYP1A2CYP2D6
SCHEMBL17234815 0.68 GAA (0.34) CYP2C19ADRA2AADRA2BADRA2C
SCHEMBL22993455 0.68 CYP2C19 (0.32) NMT1CYP2C19
SCHEMBL15730382 0.67 GRIA2 (0.41) CYP2C19CYP1A2CYP2D6HRH1HTR6
SCHEMBL24045527 0.65 GAA (0.37)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230250080-A1 ENZYME INHIBITORS KALVISTA PHARMACEUTICALS LTD (GB) 2023-08-10 US disclosed
US-20230250080-A1 ENZYME INHIBITORS KALVISTA PHARMACEUTICALS LTD (GB) 2023-08-10 US disclosed
US-11613527-B2 Enzyme inhibitors KALVISTA PHARMACEUTICALS LIMITED (GB) 2023-03-28 US disclosed
US-20220048894-A1 ENZYME INHIBITORS KALVISTA PHARMACEUTICALS LIMITED (GB) 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230250080-A1 ENZYME INHIBITORS SERPINB1, KLKB1, SERPINE1 NMT1 1774/4885CYP2C19 944/4885PDE2A 629/4885
US-11613527-B2 Enzyme inhibitors SERPINB1, KLKB1, SERPINE1 NMT1 1774/4885CYP2C19 944/4885PDE2A 629/4885
US-20220048894-A1 ENZYME INHIBITORS SERPINB1, KLKB1, SERPINE1 NMT1 1774/4885CYP2C19 944/4885PDE2A 629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.